Literature DB >> 27914853

Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.

Kathy Leung1, Marc Lipsitch2, Kwok Yung Yuen3, Joseph T Wu4.   

Abstract

BACKGROUND: Antivirals (eg, oseltamivir) are important for mitigating influenza epidemics. In 2007, an oseltamivir-resistant influenza seasonal A H1N1 strain emerged and spread to global fixation within 1 year. This event showed that antiviral-resistant (AVR) strains can be intrinsically more transmissible than their contemporaneous antiviral-sensitive (AVS) counterpart. Surveillance of AVR fitness is therefore essential. Our objective was to develop a simple method for estimating AVR fitness from surveillance data.
METHODS: We defined the fitness of AVR strains as their reproductive number relative to their co-circulating AVS counterparts. We developed a simple method for real-time estimation of AVR fitness from surveillance data. This method requires only information on generation time without other specific details regarding transmission dynamics. We first used simulations to validate this method by showing that it yields unbiased and robust fitness estimates in most epidemic scenarios. We then applied this method to two retrospective case studies and one hypothetical case study.
FINDINGS: We estimated that the oseltamivir-resistant A H1N1 strain that emerged in 2007 was 4% (95% credible interval [CrI] 3-5) more transmissible than its oseltamivir-sensitive predecessor and the oseltamivir-resistant pandemic A H1N1 strain that emerged and circulated in Japan during 2013-14 was 24% (95% CrI 17-30) less transmissible than its oseltamivir-sensitive counterpart. We show that in the event of large-scale antiviral interventions during a pandemic with co-circulation of AVS and AVR strains, our method can be used to inform optimal use of antivirals by monitoring intrinsic AVR fitness and drug pressure on the AVS strain.
INTERPRETATION: We developed a simple method that can be easily integrated into contemporary influenza surveillance systems to provide reliable estimates of AVR fitness in real time. FUNDING: Research Fund for the Control of Infectious Disease (09080792) and a commissioned grant from the Health and Medical Research Fund from the Government of the Hong Kong Special Administrative Region, Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant number U54 GM088558), Area of Excellence Scheme of the Hong Kong University Grants Committee (grant number AoE/M-12/06).
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27914853      PMCID: PMC5470942          DOI: 10.1016/S1473-3099(16)30465-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  25 in total

1.  The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Authors:  Wai Lan Wu; Siu-Ying Lau; Yixin Chen; Genyan Wang; Bobo Wing-Yee Mok; Xi Wen; Pui Wang; Wenjun Song; Tianwei Lin; Kwok-Hung Chan; Kwok-Yung Yuen; Honglin Chen
Journal:  Antiviral Res       Date:  2011-11-25       Impact factor: 5.970

2.  Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials.

Authors:  M Elizabeth Halloran; Frederick G Hayden; Yang Yang; Ira M Longini; Arnold S Monto
Journal:  Am J Epidemiol       Date:  2006-11-06       Impact factor: 4.897

3.  Emergence of drug resistance: implications for antiviral control of pandemic influenza.

Authors:  Murray E Alexander; Christopher S Bowman; Zhilan Feng; Michael Gardam; Seyed M Moghadas; Gergely Röst; Jianhong Wu; Ping Yan
Journal:  Proc Biol Sci       Date:  2007-07-22       Impact factor: 5.349

4.  Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.

Authors:  P Kramarz; Dominique Monnet; A Nicoll; C Yilmaz; B Ciancio
Journal:  Euro Surveill       Date:  2009-02-05

5.  The global spread of drug-resistant influenza.

Authors:  Dennis L Chao; Jesse D Bloom; Beth F Kochin; Rustom Antia; Ira M Longini
Journal:  J R Soc Interface       Date:  2011-08-24       Impact factor: 4.118

6.  Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.

Authors:  Emi Takashita; Maki Kiso; Seiichiro Fujisaki; Masaru Yokoyama; Kazuya Nakamura; Masayuki Shirakura; Hironori Sato; Takato Odagiri; Yoshihiro Kawaoka; Masato Tashiro
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

7.  Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Authors:  Jesse D Bloom; Lizhi Ian Gong; David Baltimore
Journal:  Science       Date:  2010-06-04       Impact factor: 47.728

8.  Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic.

Authors:  Joseph T Wu; Cheuk Kwong Lee; Benjamin J Cowling; Kwok Yung Yuen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

9.  Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.

Authors:  Elena A Govorkova; Tatiana Baranovich; Patrick Seiler; Jianling Armstrong; Andrew Burnham; Yi Guan; Malik Peiris; Richard J Webby; Robert G Webster
Journal:  Antiviral Res       Date:  2013-02-28       Impact factor: 5.970

10.  Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Authors:  Emi Takashita; Adam Meijer; Angie Lackenby; Larisa Gubareva; Helena Rebelo-de-Andrade; Terry Besselaar; Alicia Fry; Vicky Gregory; Sook-Kwan Leang; Weijuan Huang; Janice Lo; Dmitriy Pereyaslov; Marilda M Siqueira; Dayan Wang; Gannon C Mak; Wenqing Zhang; Rod S Daniels; Aeron C Hurt; Masato Tashiro
Journal:  Antiviral Res       Date:  2015-02-23       Impact factor: 10.103

View more
  8 in total

1.  The importance of the generation interval in investigating dynamics and control of new SARS-CoV-2 variants.

Authors:  Sang Woo Park; Benjamin M Bolker; Sebastian Funk; C Jessica E Metcalf; Joshua S Weitz; Bryan T Grenfell; Jonathan Dushoff
Journal:  J R Soc Interface       Date:  2022-06-15       Impact factor: 4.293

2.  Aloe Polysaccharides Inhibit Influenza A Virus Infection-A Promising Natural Anti-flu Drug.

Authors:  Zhenhong Sun; Cuilian Yu; Wei Wang; Guangfu Yu; Tingting Zhang; Lin Zhang; Jiguo Zhang; Kai Wei
Journal:  Front Microbiol       Date:  2018-09-27       Impact factor: 5.640

Review 3.  Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview.

Authors:  Ahmed Mostafa; Elsayed M Abdelwhab; Thomas C Mettenleiter; Stephan Pleschka
Journal:  Viruses       Date:  2018-09-13       Impact factor: 5.048

4.  Real-time quantification of the transmission advantage associated with a single mutation in pathogen genomes: a case study on the D614G substitution of SARS-CoV-2.

Authors:  Shi Zhao; Jingzhi Lou; Lirong Cao; Hong Zheng; Marc K C Chong; Zigui Chen; Renee W Y Chan; Benny C Y Zee; Paul K S Chan; Maggie H Wang
Journal:  BMC Infect Dis       Date:  2021-10-07       Impact factor: 3.090

5.  Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020.

Authors:  Kathy Leung; Yao Pei; Gabriel M Leung; Tommy Ty Lam; Joseph T Wu
Journal:  Euro Surveill       Date:  2021-12

6.  Genomic epidemiology of SARS-CoV-2 under an elimination strategy in Hong Kong.

Authors:  Haogao Gu; Ruopeng Xie; Dillon C Adam; Joseph L-H Tsui; Daniel K Chu; Lydia D J Chang; Sammi S Y Cheuk; Shreya Gurung; Pavithra Krishnan; Daisy Y M Ng; Gigi Y Z Liu; Carrie K C Wan; Samuel S M Cheng; Kimberly M Edwards; Kathy S M Leung; Joseph T Wu; Dominic N C Tsang; Gabriel M Leung; Benjamin J Cowling; Malik Peiris; Tommy T Y Lam; Vijaykrishna Dhanasekaran; Leo L M Poon
Journal:  Nat Commun       Date:  2022-02-08       Impact factor: 14.919

7.  The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19.

Authors:  Shi Zhao; Salihu S Musa; Marc Kc Chong; Jinjun Ran; Mohammad Javanbakht; Lefei Han; Kai Wang; Nafiu Hussaini; Abdulrazaq G Habib; Maggie H Wang; Daihai He
Journal:  J Glob Health       Date:  2021-12-25       Impact factor: 4.413

8.  The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19.

Authors:  Shi Zhao; Kai Wang; Marc K C Chong; Salihu S Musa; Mu He; Lefei Han; Daihai He; Maggie H Wang
Journal:  J Theor Biol       Date:  2022-03-21       Impact factor: 2.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.